Total Brain Partners With Mapmygenome For A Three Months Trial Of Brain Optimization Platform


Total Brain Limited (ASX: TTB), a company from the health care sector which is into the business of commercializing brain function analysis through its world’s first holistic brain optimization platform, announced that it has entered into a partnership with Mapmygenome, where TTB will be offering a three months trial of its digital services to all Mapmygenome users.

Genomepatri™, a product of Mapmygenome accesses more than 100 risk conditions associated with inherited and acquired genomic health. The assessment results offer valuable understanding into genomic predisposition to several health conditions, lifestyle tendencies and drug effectiveness. 

Through this partnership, the users of Mapmygenome will be able to complement their genetic health profile with brain health insights where they can access 12 brain capacities as well as perform the screening for the risk of mental conditions. These users will be able to access brain training, identify the area of weaknesses and work on those areas. Simultaneously, they can also enhance areas of strength.

Once the trial period gets completed, to access the services of the Total Brain services, these users will have to pay a monthly fees.

The brain optimization platform of Total Brain Limited is powered by the neuroscientific database which is a scientifically validated and the largest standardized database for digital brain assessment. Through this, the users of Total Brain Ltd can control on 12 of their brain capacities which will cover the areas of emotion, feeling, cognition and self-control.

On the other hand, Mapmygenome based on its genetic tests provides personalized health solutions. Through this, people can explore more about themselves. Mapmygenome recommends the actionable steps to the people for a better and healthier life based on the genetic health profile and health history with genetic counselling’s combined outcome.

Sponsored ad by Kalkine

With this partnership, Mapmygenome would be able to focus on preventative healthcare.

Anu Acharya, who is the CEO of Mapmygenome, is excited about the partnership with Total Brain as the users of Mapmygenome will now have a deeper insight of their brain and train their brain accordingly for the healthier outcome. She also states that the offerings made by TTB are in line with their focus on preventative healthcare through healthy habits.

Through B2C channel partners, TTB is adding its B2B channel partners in the targeted consumer markets. By entering into the partnership with Mapmygenome, Mapmygenome becomes the second consumer channel partnership for Total Brain. The users of Mapmygenome will be able to access the trial offer in the Q1 2019.

On 6 February 2019, TTB launched 40 new pieces of training and videos for the users which will help them to optimize their brain. Through its exclusive partnership with TLEX institute, the company produced exclusive breathing exercises and guided meditation.

In the last six months, the stock has generated a negative return of 31.48%. The stock last traded at A$0.037 (on 8 February 2019). The stock has a market capitalization of A$19.66 million and approximately 531.26 million outstanding shares.


This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report


Please enter your comment!
Please enter your name here